"Glimepiride Img. Pioglitazone Hcl 1Smg + Metformin Hcl (Extended Released) 500mg Tablets (uncoatedbilayered)"

"Glimepiride Img. Pioglitazone Hcl 1Smg + Metformin Hcl (Extended Released) 500mg Tablets (uncoatedbilayered)" is a bilayered tablet formulated with "Glimepiride Img. Pioglitazone Hcl 1Smg + Metformin Hcl (Extended Released) 500mg (uncoatedbilayered)". The listed active ingredient profile is "Glimepiride Img. Pioglitazone Hcl 1Smg; Metformin Hcl ", placing the product in the oral antidiabetic category. The formulation contains one or more oral glucose-lowering medicines used in clinician-directed management of type 2 diabetes mellitus. The source indicates extended release; uncoated; bilayered characteristics, which should be retained exactly because release technology can affect administration and product performance. For website cataloguing, the composition, strength, dosage form and formulation characteristics should be displayed prominently and consistently. The product description should remain factual and should not include unapproved cure, superiority, guaranteed-result or broad therapeutic claims. Clinical selection should depend on diagnosis, patient-specific factors, contraindications, concomitant medicines and professional judgement. Prescription status, warnings, interactions, adverse effects and dosing or application instructions must be checked against the current approved product label. Manufacturer, licence, storage, shelf-life, reconstitution where applicable, and market-specific regulatory details should be added only from verified product documentation.